Table 1 Demographics of the included studies comparing 2D and 3D ET
First author/year | City/country | Study type | NOS stars/Jadad score | 3D VS. 2D | Diseases/surgical approach | 3D system | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No. of participants | Gender (male/female, n) | Mean age (year)a | |||||||||
Tang Tao, 201 9[15] | Sichuan, China | RS | 7★/− | 32 | 36 | 2/30 | 1/35 | 39.25 ± 8.73 | 41.72 ± 7.94 | Thyroid cancer/via breast approach | NR |
Chen Jian, 2015 [16] | Hubei, China | RS | 8★/− | 26 | 34 | 6/20 | 6/28 | 46.15 ± 11.74 | 49.29 ± 11.61 | Thyroid diseases/via modified chest and mammary areola approach | NR |
Liu Xue-Wen, 2017 [17] | Guangdong, China | RS | 7★/− | 30 | 30 | 5/25 | 4/26 | 41.40 ± 9.07 | 40.93 ± 7.65 | Thyroid cancer/via breast approach | NR |
Huang Jue, 2020 [18] | Henan, China | RCT | −/3 | 32 | 32 | 7/25 | 10/22 | 55.27 ± 6.34 | 56.81 ± 7.10 | Thyroid cancer/via breast approach | Olympus Corporation, Japan |
Jiang Yinhai, 2019 [19] | Shandong, China | RS | 8★/− | 40 | 40 | 6/34 | 7/33 | 41.10 ± 6.80 | 43.10 ± 7.20 | Thyroid cancer/via breast approach | Viking 3D HD system, USA |
Feng Jianping, 2020 [20] | Guangdong, China | RS | 8★/− | 26 | 25 | 4/22 | 2/23 | 30.27 ± 7.95 | 31.44 ± 6.97 | Thyroid cancer/via breast approach | Viking 3D HD system, USA |
Xing Ying, 2018 [21] | Beijing, China | RCT | −/3 | 42 | 42 | 10/32 | 8/34 | 47.60 ± 8.50 | 49.30 ± 9.50 | Thyroid cancer/via modified chest and mammary areola approach | NR |
Zou Zhaowei, 2014 [22] | Guangdong, China | RS | 7★/− | 30 | 30 | 10/20 | 12/18 | 43.30 ± 7.81 | 44.40 ± 7.59 | Benign thyroid nodules/via breast approach | NR |
Jiasheng Xu, 2018 [23] | Jiangxi, China | RS | 7★/− | 88 | 92 | NR | NR | 29.51 ± 5.36 | 34.36 ± 5.53 | Benign thyroid nodules/via breast approach | NR |
Zi-Fang Zheng, 2018 [24] | Fujian, China | RS | 7★/− | 50 | 50 | 12/38 | 15/35 | 36.70 ± 7.50 | 37.30 ± 7.80 | Thyroid diseases/via the trans-thoracoareolar approach | Karl Storoz, Germany |
Zhao Bei-yong, 2020 [25] | Henan, China | RCT | −/3 | 69 | 69 | 7/62 | 9/60 | 36.85 ± 7.11 | 36.21 ± 6.97 | Benign thyroid nodules/via breast approach | NR |
Li Dongwei, 2018 [26] | Guangdong, China | RS | 8★/− | 26 | 35 | 3/23 | 5/30 | 34.60 ± 9.00 | 35.50 ± 9.20 | Benign thyroid nodules/via breast approach | Olympus Corporation, Japan |
Fan Dunhui, 2019 [27] | Gansu, China | RS | 7★/− | 35 | 35 | 19/16 | 20/15 | 41.16 ± 5.02 | 40.25 ± 4.56 | Benign thyroid nodules/via breast approach | Karl Storoz, Germany |
Li Weiqi, 2017 [28] | Guangdong, China | RCT | −/3 | 20 | 20 | 5/15 | 6/14 | 43.10 ± 7.20 | 40.70 ± 8.00 | Benign thyroid nodules/via breast approach | Karl Storoz, Germany |
Zhang Duojun, 2017 [29] | Neimenggu, China | RS | 7★/− | 37 | 37 | 4/33 | 7/30 | 36.25 ± 5.28 | 37.2 ± 7.12 | Benign thyroid nodules/via breast approach | Olympus Corporation, Japan |